Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication
IRCT20221016056190N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of amoxicillin, pantoprazole, metronidazole and bismuth subcitrate in Helicobacter pylori infection (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Eradication rate of Helicobacter pylori infection. Started Oct 2021; status: completed.
02
Drugs
amoxicillinpantoprazolemetronidazolebismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20221016056190N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221016056190N1.